review · Current Medical Research and Opinion
Conventional healthcare historically relied on generalized therapies, operating on the premise that one treatment suits diverse patient groups. Contemporary breakthroughs show the constraints of this model, prompting a transition toward targeted alternatives such as cell therapies, high molecular weight agents, personalized interventions, and gene therapies. In regenerative medicine, stem cell therapies show promise for repairing tissue, with ongoing work addressing safety and efficacy. High molecular weight treatments, including engineered peptides and proteins, offer precise targeting for drug delivery, immunotherapy, and disease modulation. In personalized healthcare, therapies tailored to individual genetic profiles, biomarkers, and mutations allow clinicians to improve efficacy and reduce adverse effects. Additionally, gene therapy tools like CRISPR-Cas9 tackle root genetic causes, creating opportunities to treat previously incurable disorders. Together, these evolving platforms aim to deliver higher therapeutic efficiency alongside reduced side effects.
Moving away from standard, uniform treatments towards therapies shaped by individual genetics and targeted mechanisms can transform patient care. These innovations offer clinicians tools to treat severe conditions with greater precision, lowering the risk of harmful side effects and offering prospective cures for previously untreatable genetic conditions.
These therapeutic modules offer practical routes for biotechnology developers and clinicians pursuing targeted therapeutics, regenerative treatments, and gene-editing solutions. Applications include engineered proteins for drug delivery, mutation-guided clinical regimens, and CRISPR-Cas9 gene interventions. While targeted mutation-specific therapies are already applied by clinicians to optimise patient outcomes, other areas such as stem cell platforms remain in ongoing research to enhance safety and efficacy.
AI-generated from the published abstract. Always read the original work before citing.
The development of therapies followed a generalized approach for a long time, assuming that a single treatment could effectively address various patient populations. However, recent breakthroughs have revealed the limitations of this one-size-fits-all paradigm. More recently, the field of therapeutics has witnessed a shift toward other modules, including cell therapies, high molecular weight remedies, personalized medicines, and gene therapies. Such advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects. Cell therapies have gained considerable attention in regenerative medicine. Stem cell-based therapies, for instance, hold promise for tissue repair and regeneration, with ongoing research focusing on enhancing their efficacy and safety. High molecular weight drugs like peptides and proteins emerged as promising therapeutics because of their high specificity and diverse biological functions. Engineered peptides and proteins are developed for targeted drug delivery, immunotherapy, and disease-modulation. In personalized medicine, tailored treatments to individuals based on specific genetic profiling, lifestyle, biomarkers, and disease characteristics are all implemented. Clinicians have tailored treatments to optimize outcomes and minimize adverse effects, using targeted therapies based on specific mutations, yielding remarkable results. Gene therapies have revolutionized the treatment of genetic disorders by directly targeting the underlying genetic abnormalities. Innovative techniques, such as CRISPR-Cas9 have allowed precise gene editing, opening up possibilities for curing previously incurable conditions. In conclusion, advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/03007995.2024.2416985
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
